
ARTERA
Precision oncology, powered by AI

ArteraAI Prostate Test

Actionable Results - Fast Turnaround
No Tissue Requirement

Personalized Care Across Prostate Cancer Continuum



Prognostic: estimates the 10-year risk of distant metastasis (DM) and prostate cancer-specific mortality (PCSM)

- In lower-risk patients, helps determine whether active surveillance may be appropriate
- In higher-risk patients, helps determine whether adding abiraterone to treatment may be appropriate

Predictive: predicts the benefit of adding short-term androgen deprivation therapy (ST-ADT) to radiotherapy

Where does the ArteraAI Prostate Test fit in the patient journey?

Screening → Diagnosis → → Treatment

Prognostic and predictive results from the ArteraAI Prostate Test help guide personalized treatment decisions along the continuum of prostate cancer, from localized to metastatic disease.

How can the prognostic and predictive results be used to guide treatment decisions?

Treatment Naive Biopsy Results Provided Across NCCN Risk Groups					Post-Prostatectomy	Metastatic
Low Risk	Favorable Intermediate Risk	Unfavorable Intermediate Risk	High Risk	Very High Risk	Biochemical Recurrence	mHSPC
10-Year Risk of Distant Metastasis (DM)					10-Year Risk of DM	Distribution of patients by MMAI-defined risk
10-Year Risk of Prostate Cancer Specific Mortality (PCSM)					5-Year Risk of DM	5-Year Risk of PCSM
Active Surveillance Insights					10-Year Risk of PCSM	
	Prediction of ST-ADT Benefit		Prediction of Abiraterone Benefit		Prediction of ADT Benefit	

Multimodal artificial intelligence (ArteraAI Prostate Test) is the only AI tool included in the NCCN Guidelines® for Prostate Cancer[1]

DOES NOT CONSUME TISSUE

Analysis uses image data from existing H&E slides with no additional staining or preparation required

RAPID TURNAROUND

Results are available 5 days after receipt of the specimen by Genekor Medical

DEVELOPED FROM LARGE DATASETS

Validated using data from over 9000 patients enrolled in multiple Phase 3 randomized trials across treatment modalities with up to 20 years of follow-up[2,3,4].

«Advanced AI Tools for prostate cancer risk stratification, such as the ArteraAI Prostate Test, are now transforming how we counsel our patients regarding treatment and outcomes.»

- Zachary Klaassen, MD, Georgia Cancer Center

Learn more about the ArteraAI Prostate Test

The ArteraAI Prostate Test is CE marked under Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) and is available in Greece through Genekor Medical.

ADT, androgen deprivation therapy; AI, artificial intelligence; DM, distant metastasis; H&E, hematoxylin and eosin; MMAI, multimodal artificial intelligence; NCCN, National Comprehensive Cancer Network; PCSM, prostate cancer-specific mortality; ST-ADT, short-term androgen deprivation therapy.

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer V.7.2026. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 9, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network. **2.** Esteva A, et al. *NPJ Digit Med.* 2022;5(1):71. **3.** Data on File. Artera, 2026. **4.** Spratt DE, et al. *NEJM Evidence.* 2023;2(8).

ARTERA

artera.ai
Artera is located at 108 First Street, Los Altos, CA 94022, USA
Artera© All Rights Reserved. September 2026, PML 021.D

AICPA SOC · HIPAA Compliance · CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS

Genekor
Committed to Biotechnological Innovation

Genekor Medical S.A.
Spaton Av. 52 | Gerakas, Greece | T: +30 210 6032 138 | F: +30 210 6032 148
info@genekor.com | www.genekor.com